Micrococcus luteus Reduction
- Dr. Nicholas Rhodes PhD; Professor Anthony Fisher PhD MD
- Airmid Healthgroup, Ireland
- Full Report
This in vitro study demonstrated the efficacy of the Defend 1050 device at removing aerosolized Micrococcus luteus bacteria. The NV1050 device is designed to reduce airborne bacteria, viruses and fungal spores in order to decrease infection rates from airborne pathogens.
Micrococcus luteus was aerosolized into a 58.8m3 room containing the NV1050 for evaluation. The NV1050 was evaluated at fan speed 5 and air samples were taken every 5 or 10 minutes depending on the test in order to quantify the reduction capabilities of the device at maximum speed. Control trial data was subtracted from the NV1050 trial data to yield net LOG reduction for bioaerosol reductions. An external company was used to count samples to ensure the results were blinded.
The NV1050 average bacterial reduction of 99.2% (2.08 log) in 60 minutes in a 58.8 m3 room.